北京
禮來股價跌4.5%，諾和諾德股價上漲6%。禮來公司新推出的口服減肥藥Foundayo上市初期處方量遠遜于競爭對手，令市場對其能否在口服減肥藥賽道追趕諾和諾德產生疑慮。據RBC Capital Markets分析師Trung Huynh援引IQVIA數據，Foundayo上市第二周共產生3707張處方，而諾和諾德口服版Wegovy在上市第二周錄得18410張處方，差距懸殊。
本文源自：金融界AI電報
特別聲明：以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布，本平臺僅提供信息存儲服務。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
